AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Psyched Wellness Ltd

$0.01 -$0.00 (-37.50%)
OTC · 14 Sep 2026 20:00 UTC
Previous Close
$0.01
Day Range
$0.01 - $0.01
Year Range
$0$0.02
Market Cap
1.57M
AVG Volume
109.42K
Trailing/Forward PE
-0.29/-
PEG ratio
0.06
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (CAD) · TTM
0200K400K600K800K24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF Revenue (CAD) · TTM by quarter
PeriodRevenue (CAD) · TTM
26 Q2746.27K
26 Q1627.28K
25 Q4472.08K
25 Q3360.3K
25 Q2451.56K
25 Q1642.57K
24 Q4623.16K
24 Q3612.52K
24 Q2469.24K
24 Q1326K
Net Income (CAD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF Net Income (CAD) · TTM by quarter
PeriodNet Income (CAD) · TTM
26 Q2-5.37M
26 Q1-5.54M
25 Q4-5.03M
25 Q3-4.43M
25 Q2-4.87M
25 Q1-4.39M
24 Q4-4.26M
24 Q3-4.73M
24 Q2-3.62M
24 Q1-3.11M
Operating Income (CAD) · TTM
-8M-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF Operating Income (CAD) · TTM by quarter
PeriodOperating Income (CAD) · TTM
26 Q2-5.76M
26 Q1-5.51M
25 Q4-5.16M
25 Q3-6M
25 Q2-4.9M
25 Q1-4.83M
24 Q4-4.52M
24 Q3-3.52M
24 Q2-3.91M
24 Q1-3.24M
EBITDA (CAD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF EBITDA (CAD) · TTM by quarter
PeriodEBITDA (CAD) · TTM
26 Q2-5.75M
26 Q1-5.5M
25 Q4-5.16M
25 Q3-4.43M
25 Q2-4.87M
25 Q1-4.82M
24 Q4-4.51M
24 Q3-4.87M
24 Q2-3.73M
24 Q1-3.07M
Cash Flows (CAD) · TTM
-6M-4M-2M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF Cash Flows (CAD) · TTM by quarter
PeriodCash Flows (CAD) · TTM
26 Q2-4.42M
26 Q1-5.1M
25 Q4-4.05M
25 Q3-3.52M
25 Q2-3.41M
25 Q1-2.92M
24 Q4-3.1M
24 Q3-3.4M
24 Q2-3.05M
24 Q1-2.78M
EPS (CAD) · TTM
-0.03-0.02-0.01024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF EPS (CAD) · TTM by quarter
PeriodEPS (CAD) · TTM
26 Q2-0.02
26 Q1-0.02
25 Q4-0.02
25 Q3-0.01
25 Q2-0.02
25 Q1-0.02
24 Q4-0.02
24 Q3-0.02
24 Q2-0.02
24 Q1-0.02
Expenses (CAD) · TTM
-2M02M4M6MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF Expenses (CAD) · TTM by quarter
PeriodExpenses (CAD) · TTM
26 Q25.79M
26 Q15.49M
25 Q45.1M
25 Q34.49M
25 Q24.98M
25 Q15.04M
24 Q44.7M
24 Q35.24M
24 Q24.05M
24 Q13.18M
Shares Outstanding (CAD) · TTM
-1.5M-1M-500K0Buybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
PSYCF Shares Outstanding (CAD) · TTM by quarter
PeriodShares Outstanding (CAD) · TTM
26 Q2-285.96K
26 Q1-489.26K
25 Q4-612.32K
25 Q3-19.49K
25 Q2-655.63K
25 Q1-734.92K
24 Q4-612.93K
24 Q3-1.35M
24 Q2-699.72K
24 Q1-435.45K
Free Cash Flow Yield
-300%-200%-100%0%med -64.86%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
PSYCF Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-167.11%
Sep 26-177.78%
Sep 26-209.45%
Aug 26-254.25%
Aug 26-233.46%
Aug 26-212.32%
Aug 26-211.35%
Jul 26-180.18%
Jul 26-174.18%
Jul 26-157.57%
Jul 26-160.11%
Jul 26-178.03%
Jun 26-162.4%
Jun 26-134.42%
Jun 26-135.85%
Jun 26-120.76%
May 26-120.36%
May 26-112.9%
May 26-102.13%
May 26-115.34%
May 26-114.81%
Apr 26-126.82%
Apr 26-102.96%
Apr 26-126.79%
Apr 26-124.52%
Mar 26-109.55%
Mar 26-102.32%
Mar 26-127.89%
Mar 26-107.84%
Feb 26-89.4%
Feb 26-115.8%
Feb 26-81.41%
Feb 26-117.35%
Jan 26-99.49%
Jan 26-92.72%
Jan 26-87.62%
Jan 26-87.65%
Jan 26-111.02%
Dec 25-81.07%
Dec 25-67.98%
Dec 25-63.24%
Dec 25-80.23%
Nov 25-59.43%
Nov 25-64.34%
Nov 25-49.77%
Nov 25-67.7%
Oct 25-67.36%
Oct 25-60.18%
Oct 25-60.08%
Oct 25-64.8%
Oct 25-62.31%
Sep 25-67.67%
Sep 25-53.01%
Sep 25-58.33%
Sep 25-66.12%
Aug 25-71.52%
Aug 25-61.87%
Aug 25-59.52%
Aug 25-59.78%
Aug 25-59.63%
Jul 25-35.47%
Jul 25-56.87%
Jul 25-39.05%
Jul 25-43.24%
Jun 25-52.1%
Jun 25-43.24%
Jun 25-63.48%
Jun 25-56.58%
May 25-55.58%
May 25-61.33%
May 25-56.32%
May 25-62.39%
May 25-56.95%
Apr 25-60.23%
Apr 25-64.92%
Apr 25-70.67%
Apr 25-64.42%
Mar 25-60.24%
Mar 25-54.42%
Mar 25-52.52%
Mar 25-57.28%
Feb 25-49.69%
Feb 25-49.18%
Feb 25-48.44%
Feb 25-51.53%
Jan 25-56.5%
Jan 25-54.93%
Jan 25-51.16%
Jan 25-63.04%
Jan 25-63.42%
Dec 24-64.16%
Dec 24-64.49%
Dec 24-57.67%
Dec 24-58.63%
Nov 24-59.21%
Nov 24-58.52%
Nov 24-53.44%
Nov 24-47.7%
Nov 24-72.58%
Oct 24-68.76%
Price to Sales
05101520med 8.74Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
PSYCF Price to Sales by quarter
PeriodPrice to Sales
Sep 263.54
Sep 263.33
Sep 262.83
Aug 263.2
Aug 263.49
Aug 263.83
Aug 263.85
Jul 264.52
Jul 264.67
Jul 265.16
Jul 265.08
Jul 264.57
Jun 265.01
Jun 266.05
Jun 265.99
Jun 266.74
May 266.76
May 267.61
May 268.41
May 267.45
May 267.48
Apr 266.77
Apr 268.34
Apr 266.77
Apr 266.9
Mar 267.84
Mar 268.39
Mar 266.72
Mar 267.96
Feb 2610.93
Feb 268.44
Feb 2612
Feb 268.33
Jan 269.82
Jan 2610.54
Jan 2611.15
Jan 2611.15
Jan 268.8
Dec 2512.05
Dec 2514.38
Dec 2515.45
Dec 2512.18
Nov 2512.69
Nov 2511.72
Nov 2515.15
Nov 2511.14
Oct 2511.19
Oct 2512.53
Oct 2512.55
Oct 2511.64
Oct 2512.1
Sep 2511.14
Sep 2514.23
Sep 2512.93
Sep 2511.41
Aug 2510.54
Aug 257.35
Aug 257.64
Aug 257.61
Aug 257.62
Jul 2512.82
Jul 257.99
Jul 2511.64
Jul 2510.51
Jun 258.73
Jun 2510.51
Jun 257.16
Jun 258.03
May 258.18
May 258.12
May 258.84
May 257.98
May 258.75
Apr 258.27
Apr 257.67
Apr 257.05
Apr 257.73
Mar 258.27
Mar 259.15
Mar 259.49
Mar 258.7
Feb 2510.03
Feb 2511.3
Feb 2511.47
Feb 2510.78
Jan 259.83
Jan 2510.12
Jan 2510.86
Jan 258.81
Jan 258.76
Dec 248.66
Dec 248.62
Dec 249.64
Dec 249.48
Nov 249.38
Nov 2411.1
Nov 2412.16
Nov 2413.62
Nov 248.95
Oct 249.45
Price to Book
00.511.522.5med 0.94Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
PSYCF Price to Book by quarter
PeriodPrice to Book
Sep 261.56
Sep 261.47
Sep 261.24
Aug 261.11
Aug 261.21
Aug 261.33
Aug 261.33
Jul 261.57
Jul 261.62
Jul 261.79
Jul 261.76
Jul 261.58
Jun 261.74
Jun 262.1
Jun 262.08
Jun 262.34
May 262.34
May 261.16
May 261.28
May 261.13
May 261.14
Apr 261.03
Apr 261.27
Apr 261.03
Apr 261.05
Mar 261.19
Mar 261.28
Mar 261.02
Mar 261.21
Feb 260.91
Feb 260.7
Feb 261
Feb 260.69
Jan 260.82
Jan 260.88
Jan 260.93
Jan 260.93
Jan 260.73
Dec 251
Dec 251.2
Dec 251.29
Dec 251.01
Nov 251.07
Nov 250.99
Nov 251.28
Nov 250.94
Oct 250.95
Oct 251.06
Oct 251.06
Oct 250.98
Oct 251.02
Sep 250.94
Sep 251.2
Sep 251.09
Sep 250.96
Aug 250.89
Aug 250.73
Aug 250.76
Aug 250.75
Aug 250.75
Jul 251.27
Jul 250.79
Jul 251.15
Jul 251.04
Jun 250.86
Jun 251.04
Jun 250.71
Jun 250.8
May 250.81
May 250.68
May 250.74
May 250.67
May 250.73
Apr 250.69
Apr 250.64
Apr 250.59
Apr 250.65
Mar 250.69
Mar 250.77
Mar 250.79
Mar 250.73
Feb 250.84
Feb 250.88
Feb 250.89
Feb 250.84
Jan 250.76
Jan 250.79
Jan 250.84
Jan 250.68
Jan 250.68
Dec 240.67
Dec 240.67
Dec 240.75
Dec 240.74
Nov 240.73
Nov 240.59
Nov 240.65
Nov 240.72
Nov 240.48
Oct 240.5
Psyched Wellness Ltd
PSYCF
Stockpicker

Video analysis: PSYCF

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: PSYCF

Psyched Wellness Announces Secured Term Loan

newsfilecorp.com · 10 Sep 2026

Psyched Wellness Announces Secured Term Loan

Toronto, Ontario--(Newsfile Corp. - September 10, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund I, L.P.

Psyched Wellness Announces Secured Term Loan

newsfilecorp.com · 5 Aug 2026

Psyched Wellness Announces Secured Term Loan

Toronto, Ontario--(Newsfile Corp. - August 5, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched Wellness"), a life sciences company focused on the production and distribution of Amanita Muscaria-derived health and wellness products, announces that it has entered into secured term notes (the "Notes") with Gotham Green Fund III, L.P.

Psyched Wellness Launches Strategic Review to Unlock Shareholder Value

newsfilecorp.com · 29 Jul 2026

Psyched Wellness Launches Strategic Review to Unlock Shareholder Value

Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) ("Psyched Wellness" or the "Company"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, announces that its Board of Directors has commenced a strategic review process designed to evaluate opportunities to enhance and accelerate value creation for shareholders ("Strategic Review").

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.